Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 82, Issue 1, 1999, Pages 107-110

  Kodama, Junichi ^a   Miyagi, Yasunari ^a   Seki, Noriko ^a   Tokumo, Keizo ^a   Mitsuo Yoshinouchi, ^a   Kobashi, Yuuji ^a   Okuda, Hiroyuki ^a   Kudo, Takafumi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

C reactive protein; Epithelial ovarian cancer; Prognostic factor

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 0032894141     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00227-9     Document Type: Article

References (19)

1. Berek J.S., Chung C., Kaldi K., Watson J.M., Knox R.M., Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 164:1991;1038-1043.
2. Moradi M.M., Carson L.F., Weinberg J.B., Haney A.F., Twiggs L.B., Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer. 72:1993;2433-2440.
3. Scambia G., Testa U., Panici P.B.et al. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer. 57:1994;318-323.
4. van der Zee A.G., de Cuyper E.M., Limburg P.C.et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 75:1995;1004-1009.
5. Tempfer C., Zeisler H., Sliutz G., Haeusler G., Hanzal E., Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol. 66:1997;27-30.
6. Scambia G., Testa U., Benedetti-Panici P.et al. Prognostic significance of interleukin-6 serum levels in patients with ovarian cancer. Br J Cancer. 71:1995;354-356.
7. Oka M., Yamamoto K., Takahashi M.et al. Relationship between serum levels of interleukin-6, various disease parameters, and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 56:1996;2776-2780.
8. Wu C.W., Wang S.R., Chao M.F.et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol. 91:1996;1417-1422.
9. Fearon K.C.H., McMillan D.C., Preston T., Winstanley F.P., Cruickshank A.M., Shenkin A. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg. 213:1991;26-31.
10. Serov S.F., Scully R.E., Sobin L.H. Histological typing of ovarian tumors. In: World Health Organization. International histological classification of tumors. Genova: World Health Organization 1973.
11. Cannistra S.A. Cancer of the ovary. N Engl J Med. 329:1993;1550-1559.
12. Watson J.M., Sensintaffar J.L., Berek J.S., Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 50:1990;6959-6965.
13. Serve H., Steinhauser G., Oberberg D., Flegel W.A., Northoff H., Berdel W.E. Studies on the interaction between interleukin-6 and human malignant nonhematopoietic cell lines. Cancer Res. 51:1991;3862-3866.
14. Guillaume T., Sekhavat M., Rubinstein D.B., Hamdan O., Symann M.L. Transcription of genes encoding granulocyto-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines. Cancer Res. 53:1993;3139-3144.
15. Plante M., Rubin S.C., Wong G.Y., Federici M.G., Finstad C.L., Gastl G.A. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 73:1994;1882-1888.
16. Ballou S.P., Kushner I. C-reactive protein and the acute phase response. Adv Inter Med. 37:1992;313-336.
17. Hamoudi W.H., Baum L.L. Anti-C-reactive protein inhibits the calcium-dependent stage of natural killer cell activation. J Immunol. 146:1991;2873-2878.
18. Gransson J., Jonsson S., Lasson A. Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur J Surg Oncol. 22:1996;607-617.
19. Gastl G., Plante M., Finstad C.L.et al. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol. 83:1993;433-441.